LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Inicio・Lista de Acciones・Ardelyx Inc

Ardelyx Inc

Cerrado

SectorSalud

6.2 -0.8

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

6.02

Máximo

6.26

Métricas clave
By Trading Economics
Ingresos	562K -407K
Ventas	15M 125M
BPA	-0.002
Margen de beneficio	-0.325
Empleados	489
EBITDA	4.5M 10M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+161.24% upside

Dividendos
By Dow Jones
Próximas Ganancias	30 abr 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-82M 1.6B
Apertura anterior	7
Cierre anterior	6.2

Noticias sobre sentimiento de mercado

By Acuity

42%

58%

132 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

3.62 / 3.95 Soporte y Resistencia

Ardelyx Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

6 mar 2026, 19:32 UTC

Adquisiciones, fusiones, absorciones

Diana Shipping Increases Offer to Acquire Genco -- Update

6 mar 2026, 17:44 UTC

Adquisiciones, fusiones, absorciones

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

6 mar 2026, 22:26 UTC

Noticias de Eventos Importantes

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6 mar 2026, 22:07 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6 mar 2026, 22:03 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

6 mar 2026, 22:03 UTC

Charlas de Mercado

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6 mar 2026, 21:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

6 mar 2026, 21:37 UTC

Ganancias

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6 mar 2026, 21:25 UTC

Noticias de Eventos Importantes

How The Iran War Impacts Ukraine. -- Barrons.com

6 mar 2026, 21:17 UTC

Ganancias

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6 mar 2026, 20:50 UTC

Ganancias

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6 mar 2026, 20:46 UTC

Ganancias

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6 mar 2026, 20:31 UTC

Noticias de Eventos Importantes

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6 mar 2026, 20:18 UTC

Charlas de Mercado

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6 mar 2026, 20:12 UTC

Charlas de Mercado

Noticias de Eventos Importantes

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6 mar 2026, 19:10 UTC

Charlas de Mercado

Noticias de Eventos Importantes

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6 mar 2026, 18:54 UTC

Charlas de Mercado

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6 mar 2026, 18:44 UTC

Charlas de Mercado

Noticias de Eventos Importantes

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6 mar 2026, 18:08 UTC

Ganancias

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mar 2026, 18:04 UTC

Ganancias

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mar 2026, 18:04 UTC

Ganancias

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6 mar 2026, 17:49 UTC

Charlas de Mercado

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6 mar 2026, 17:46 UTC

Noticias de Eventos Importantes

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6 mar 2026, 17:40 UTC

Charlas de Mercado

Ganancias

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6 mar 2026, 17:40 UTC

Ganancias

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6 mar 2026, 17:32 UTC

Charlas de Mercado

Noticias de Eventos Importantes

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6 mar 2026, 17:28 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6 mar 2026, 17:20 UTC

Charlas de Mercado

Ganancias

Auto & Transport Roundup: Market Talk

6 mar 2026, 17:20 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

6 mar 2026, 17:20 UTC

Adquisiciones, fusiones, absorciones

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Comparación entre iguales

Cambio de precio

Ardelyx Inc Esperado

Precio Objetivo

By TipRanks

161.24% repunte

Estimación a 12 meses

Media 16.38 USD 161.24%

Máximo 19 USD

Mínimo 13 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ardelyx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Ardelyx Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

3.62 / 3.95Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Recent bearish events outweigh bullish events.

Sentimiento

By Acuity

132 / 351 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.